Patterns and determinants of dementia pharmacotherapy in a population-based cohort of home care clients

Drugs and Aging

Volumn 30, Issue 7, 2013, Pages 569-585

  Maxwell, Colleen J ^a,b,c   Vu, Mary ^a   Hogan, David B ^b,d   Patten, Scott B ^b   Jantzi, Micaela ^a   Kergoat, Marie Jeanne ^e   Jetté, Nathalie ^b,f   Bronskill, Susan E ^c,g   Heckman, George ^a   Hirdes, John P ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e CENTRE DE RECHERCHE   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HYPNOTIC AGENT; MEMANTINE; NEUROLEPTIC AGENT; RIVASTIGMINE;

ADULT; AGED; AGGRESSION; ALZHEIMER DISEASE; ANXIETY; ARTICLE; CANADA; CAREGIVER BURDEN; CLINICAL PRACTICE; COGNITIVE DEFECT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DELUSION; DEMENTIA; DEMOGRAPHY; DISEASE SEVERITY; DRUG UTILIZATION; DYSPHAGIA; FEMALE; FUNCTIONAL DISEASE; GERIATRIC PATIENT; HALLUCINATION; HEALTH CARE NEED; HEALTH CARE QUALITY; HEALTH STATUS; HOME CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEX DIFFERENCE; SOCIOECONOMICS; WANDERING BEHAVIOR;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; DEMENTIA; FEMALE; GERIATRIC ASSESSMENT; HEALTH STATUS; HOME CARE SERVICES; HUMANS; MALE; MEMANTINE; MIDDLE AGED;

EID: 84879539678     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-013-0083-y     Document Type: Article

References (69)

1. World Health Organization and Alzheimer's Disease International. Dementia: a public health priority. Geneva: World Health Organization; 2012.
2. Jakobsen M, Poulsen PB, Reiche T, et al. Costs of informal care for people suffering from dementia: evidence from a Danish survey. Dement Geriatr Cogn Dis Extra. 2011;1(1):418-28.
3. Hill J, Fillit H, Thomas SK, et al. Functional impairment, healthcare costs and the prevalence of institutionalisation in patients with Alzheimer's disease and other dementias. Pharmacoeconomics. 2006;24(3):265-80.
4. Leicht H, Heinrich S, Heider D, et al. Net costs of dementia by disease stage. Acta Psychiatr Scand. 2011;124(5):384-95.
5. Smetanin P, Kobak P, Briante C, Stiff D, Sherman G, Ahmad S. Rising tide: the impact of dementia in Canada 2008 to 2038. Toronto: Alzheimer Society of Canada; 2009.
6. Health Council of Canada. Seniors in need, caregivers in distress: what are the home care profiles for seniors in Canada? Toronto. ON: Health Council of Canada; 2012.
7. Canadian Institutes for Health Information. Caring for seniors with Alzheimer's and other forms of dementia. https://secure.cihi.ca/free-products/ Dementia-AIB-2010-EN.pdf. Accessed 22 Dec 2012.
8. Vu M, Hogan DB, Patten SB, Jetté N, Bronskill SE, Heckman G, Kergoat M-J, Hirdes JP, Chen J, Zehr MM, Maxwell CJ. A comprehensive profile of the sociodemographic, psychosocial and health characteristics of Ontario home care clients with dementia. CDIC; 2012 (submitted).
9. Brayne C, David D. Making Alzheimer's and dementia research fit for population. Lancet. 2012;380(9851):1441-3.
10. Schoenmaker N, Van Gool WA. The age gap between patients in clinical studies and in the general population: a pitfall for dementia research. Lancet Neurol. 2004;3(10):627-30.
11. Gill SS, Bronskill SE, Mamdani M, et al. Representation of patients with dementia in clinical trials of donepezil. Can J Clin Pharmacol. 2004;11(2):e274-85.
12. Hogan DB, Bailey P, Black S, et al. Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. CMAJ. 2008;179(10):1019-26.
13. Herrmann N, Gauthier S. Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease. CMAJ. 2008;179(12):1279-87.
14. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt H-P, et al. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ. 2005;331(7512):321-7.
15. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006(1):CD005593.
16. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006(2):CD003154.
17. Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012(3):CD006504.
18. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148(5):379-97.
19. Knapp M, Iemmi V, Romeo R. Dementia care costs and outcomes: a systematic review. Int J Geriatr Psychiatry. 2012. doi: 10.1002/gps.3864.
20. Pariente A, Fourrier-Réglat A, Ducruet T, et al. Antipsychotic use and myocardial infarction in older patients with treated dementia. Arch Intern Med. 2012;172(8):648-53.
21. Hernandez RK, Farwell W, Cantor MD, et al. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the Veterans Affairs New England Healthcare System. J Am Geriatr Soc. 2009;57(11):1997-2003.
22. Gill SS, Anderson GM, Fischer HD, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors. A population-based cohort study. Arch Intern Med. 2009;169(9):867-73.
23. Carnahan RM, Lund BC, Perry PJ, et al. The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice? J Am Geriatr Soc. 2004;52(12):2082-7.
24. Dhalla IA, Anderson GM, Mamdani MM, et al. Inappropriate prescribing before and after nursing home admission. J Am Geriatr Soc. 2002;50(6):995-1000.
25. Barro-Belaygues N, van Kan GA, Rolland Y, et al. Patterns of dementia treatment use in assisted living facilities: a cross-sectional study of 1975 demented residents. J Am Med Dir Assoc. 2011;12(9):648-54.
26. Rosenblatt A, Samus QM, Onyike CU, et al. Acetylcholinesterase inhibitors in assisted living: patterns of use and association with retention. Int J Geriatr Psychiatry. 2008;23(2):178-84.
27. Parsons C, Briesacher BA, Givens JL, et al. Cholinesterase inhibitor and memantine use in newly admitted nursing home residents with dementia. J Am Geriatr Soc. 2011;59(7):1253-9.
28. Seitz DP, Gruneir A, Conn DK, et al. Cholinesterase inhibitor use in US nursing homes: results from the National Nursing Home Survey. J Am Geriatr Soc. 2009;57(12):2269-74.
29. Gruber-Baldini AL, Stuart B, Zuckerman IH, et al. Treatment of dementia in community-dwelling and institutionalized Medicare beneficiaries. J Am Geriatr Soc. 2007;55(10):1508-16.
30. Pedone C, Lapane KL, Mor V, et al. Donepezil use in US nursing homes. Aging Clin Exp Res. 2004;16(1):60-7.
31. Zhu CW, Livote EE, Kahle-Wrobleski K, et al. Longitudinal medication usage in Alzheimer disease patients. Alzheimer Dis Assoc Disord. 2010;24(4):354-9.
32. Hoffmann F, van den Bussche H, Wiese B, et al. Impact of geriatric comorbidity and polypharmacy on cholinesterase inhibitors prescribing in dementia. BMC Psychiatry. 2011;6(11):190.
33. Schneider LS, Insel PS, Weiner MW, for the Alzheimer's Disease Neuroimaging Initiative. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Neurol. 2011;68(1):58-66.
34. Franchi C, Lucca U, Tettamanti M, et al. Cholinesterase inhibitor use in Alzheimer's disease: the EPIFARM-Elderly Project. Pharmacoepidemiol Drug Saf. 2011;20(5):497-505.
35. Hernandez S, McClendon MJ, Zhou X-H, et al. Pharmacological treatment of Alzheimer's disease: effect of race and demographic variables. J Alzheimers Dis. 2010;19(2):665-72.
36. Formiga F, Fort I, Robles MJ, et al. Lower Barthel Index scores predict less prescription of pharmacological therapy in elderly patients with Alzheimer disease. Dement Geriatr Cogn Disord. 2010;29(3):198-203.
37. Amuah JE, Hogan DB, Eliasziw M, et al. Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease. Pharmacoepidemiol Drug Saf. 2010;19(7):670-9.
38. Pariente A, Pinet M, Moride Y, et al. Factors associated with persistence of cholinesterase inhibitor treatments in the elderly. Pharmacoepidemiol Drug Saf. 2010;19(7):680-6.
39. McClendon MJ, Hernandez S, Smyth KA, et al. Memantine and acetylcholinesterase inhibitor treatment in cases of CDR 0.5 or questionable impairment. J Alzheimers Dis. 2009;16(3):577-83.
40. Herrmann N, Gill SS, Bell CM, et al. A population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soc. 2007;55(10):1517-23.
41. Belle SH, Zhang S, Czaja SJ, et al. Use of cognitive enhancement medication in persons with Alzheimer disease who have a family caregiver: results from the Resources for Enhancing Alzheimer's Caregiver Health (REACH) project. Am J Geriatr Psychiatry. 2004;12(3):250-7.
42. Canadian Home Care Association. Portraits of Home Care in Canada. Mississauga: CHCA; 2008.
43. Canadian Institute for Health Information. Home Care Reporting System (HCRS) Privacy Impact Assessment. Ottawa: Canadian Institutes for Health Information; 2006.
44. Hirdes JP, Ljunggren G, Morris JN, et al. Reliability of the interRAI suite of assessment instruments: a 12-country study of an integrated health information system. BMC Health Serv Res. 2008;30(8):277.
45. Landi F, Tua E, Onder G, et al. Minimum data set for home care: a valid instrument to assess frail older people living in the community. Med Care. 2000;38(12):1184-90.
46. Morris JN, Fries BE, Steel K, et al. Comprehensive clinical assessment in community setting: applicability of the MDS-HC. J Am Geriatr Soc. 1997;45(8):1017-24.
47. Poss JW, Jutan NM, Hirdes JP, et al. A review of evidence on the reliability and validity of Minimum Data Set data. Healthc Manage Forum. 2008;21(1):33-9.
48. Morris JN, Fries BE, Mehr DR, et al. MDS Cognitive Performance Scale. J Gerontol. 1994;49(4):M174-82.
49. Morris JN, Fries BE, Morris SA. Scaling ADLs within the MDS. J Gerontol A Biol Sci Med Sci. 1999;54(11):M546-53.
50. Hirdes JP, Frijters DH, Teare GF. The MDS-CHESS scale: a new measure to predict mortality in institutionalized older people. J Am Geriatr Soc. 2003;51(1):96-100.
51. Burrows AB, Morris JN, Simon SE, et al. Development of a Minimum Data Set-based depression rating scale for use in nursing homes. Age Ageing. 2000;29(2):165-72.
52. Hartmaier SL, Sloane PD, Guess HA, et al. Validation of the Minimum Data Set Cognitive Performance Scale: agreement with the Mini-Mental State Examination. J Gerontol A Biol Sci Med Sci. 1995;50(2):M128-33.
53. Perlman CM, Hirdes JP. The Aggressive Behavior Scale: a new scale to measure aggression based on the Minimum Data Set. J Am Geriatr Soc. 2008;56(12):2298-303.
54. Ontario Ministry of Health and Long-Term Care. Ministry Programs: Ontario Drug Benefit Program. http://www.health.gov.on.ca/en/public/programs/drugs/ programs/odb/odb.aspx. Accessed 22 Dec 2012.
55. Ontario Ministry of Health and Long-Term Care. Ontario Drug Benefit Program: limited use (LU) drug products. http://www.health.gov.on.ca/en/public/ programs/drugs/programs/odb/opdp-limited-use.aspx. Accessed 22 Dec 2012.
56. Canadian Pharmacists Association. Compendium of pharmaceuticals and specialties. Ottawa: Canadian Pharmacists Association; 2012.
57. Gambassi G, Landi F, Peng L, et al. Validity of diagnostic and drug data in standardized nursing home resident assessments: potential for geriatric pharmacoepidemiology. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology. Med Care. 1998;36(2):167-79.
58. Mor V, Intrator O, Unruh MA, et al. Temporal and geographic variation in the validity and internal consistency of the Nursing Home Resident Assessment Minimum Data Set 2.0. BMC Health Serv Res. 2011;15(11):78.
59. Wodchis WP, Naglie G, Teare GF. Validating diagnostic information on the Minimum Data Set in Ontario hospital-based long-term care. Med Care. 2008;46(8):882-7.
60. Hoffmann F, van den Bussche H, Glaeske G, et al. Eight-year prescription trends of memantine and cholinesterase inhibitors among persons 65 years and older in Germany. Int Clin Psychopharmacol. 2010;25(1):29-36.
61. Mamdani M, Rapoport M, Shulman KI, et al. Mental health-related drug utilization among older adults. Prevalence, trends and costs. Am J Geriatr Psychiatry. 2005;13(10):892-900.
62. Schneider LS. Discontinuing donepezil or starting memantine for Alzheimer's disease. N Engl J Med. 2012;366(10):957-9.
63. Tariot PN, Farlow MR, Grossberg GT, for the Memantine Study Group, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317-24.
64. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med. 2012;366(10):893-903.
65. Vidal J-S, Lacombe J-M, Dartigues J-F, et al. Memantine therapy for Alzheimer disease in real-world practice. An observational study in a large representative sample of French patients. Alzheimer Dis Assoc Disord. 2008;22(2):125-30.
66. Gilligan AM, Malone DC, Warholak TL, et al. Racial and ethnic disparities in Alzheimer's disease pharmacotherapy exposure: an analysis across four state Medicaid populations. Am J Geriatr Pharmacother. 2012;10(5):303-12.
67. Vigen CLP, Mack WJ, Keefe RSE, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry. 2011;168(8):831-9.
68. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191-210.
69. Boudreau DM, Yu O, Gray SL, et al. Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. J Am Geriatr Soc. 2011;59(11):2069-76.